Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SLC5A2 | P31639 | 11/20 | 0.45 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.44 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.42 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14222066 | 0.88 | NPC1 (0.46) | NPC1RAB9ASLC5A2SLC5A1LGALS8 | |
| SCHEMBL6225076 | 0.86 | NPC1 (0.47) | NPC1RAB9ASLC5A2SLC5A1LGALS8 | |
| SCHEMBL14490090 | 0.85 | SLC6A2 (0.54) | SLC5A2LGALS8LGALS9LGALS1LGALS3 | |
| SCHEMBL14490084 | 0.85 | TACR2 (0.42) | NPC1RAB9ASLC5A2SLC5A1SLC6A2 | |
| SCHEMBL11026134 | 0.83 | SLC5A2 (0.48) | NPC1RAB9ASLC5A2SLC5A1 | |
| SCHEMBL17898753 | 0.82 | IDO1 (0.42) | NPC1RAB9ASLC5A2SLC5A1 | |
| SCHEMBL13380951 | 0.82 | LGALS8 (0.53) | NPC1RAB9ASLC5A2SLC5A1LGALS8 | |
| SCHEMBL6947007 | 0.82 | LGALS8 (0.53) | NPC1RAB9ASLC5A2SLC5A1LGALS8 | |
| SCHEMBL8625287 | 0.82 | SLC5A2 (0.47) | NPC1RAB9ASLC5A2SLC5A1LGALS8 | |
| SCHEMBL15937685 | 0.81 | IDO1 (0.41) | NPC1RAB9ASLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081708-A1 | ANTICOAGULANT COMPOUNDS | ENDOTIS PHARMA (FR) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081708-A1 | ANTICOAGULANT COMPOUNDS | SERPINC1, F2, FUT5 | NPC1 1414/4885RAB9A 3096/4885SLC5A2 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.